<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="100030">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01802385</url>
  </required_header>
  <id_info>
    <org_study_id>S4 0296-01</org_study_id>
    <secondary_id>R01NS086312-01</secondary_id>
    <nct_id>NCT01802385</nct_id>
  </id_info>
  <brief_title>Adjunctive Sertraline for the Treatment of HIV-Associated Cryptococcal Meningitis</brief_title>
  <acronym>ASTRO-CM</acronym>
  <official_title>Adjunctive Sertraline for the Treatment of HIV-Associated Cryptococcal Meningitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Minnesota - Clinical and Translational Science Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Infectious Disease Institute, Kampala, Uganda</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Neurological Disorders and Stroke (NINDS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Mbarara University of Science and Technology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ifakara Health Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Minnesota - Clinical and Translational Science Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase III trial to determine whether adjunctive sertraline will lead to improved
      survival 18-week survival.

      There was an initial phase I/II unmasked dose finding pharmacokinetic study of CSF
      concentrations in 172 persons conducted from August 2013 to August 2014.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase III randomized trial to evaluate whether sertraline when added to standard
      amphotericin-based therapy for cryptococcal meningitis, will lead to improved survival .
      Cryptococcal meningitis diagnosis will be made via CSF cryptococcal antigen (CRAG) at time
      of lumbar puncture (LP) with confirmation by CSF culture. After informed consent, subjects
      that meet eligibility requirements will be able to enter study. A non-randomized phase I
      dose-escalation study will first be conducted to help optimize dosing for a larger
      randomized phase II study.

      Phase III Design: Subjects will be randomized to standard induction therapy with masked
      placebo or sertraline at 400mg/day. We will use a permutated block randomization in a 1:1
      allocation (n=275 per arm). Total anticipated enrollment: 550 subjects.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2015</start_date>
  <completion_date type="Anticipated">July 2018</completion_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Survival</measure>
    <time_frame>18 weeks</time_frame>
    <description>18-week survival. The comparison will be between sertraline 400mg group and placebo</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
    <time_frame>18 weeks</time_frame>
    <description>Safety and tolerability of adjunctive sertraline (grade 4-5) adverse reactions)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intolerance</measure>
    <time_frame>18 weeks</time_frame>
    <description>Time to dose-reduction for intolerance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microbiologic</measure>
    <time_frame>14 days</time_frame>
    <description>2 week CSF culture sterility</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurocognitive Performance</measure>
    <time_frame>14 weeks</time_frame>
    <description>Quantitative neurocognitive performance score (QNPZ-8) and Center for Epidemiologic Studies in Depression (CES-D) scale at 14 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Early Fungicidal Activity</measure>
    <time_frame>14 days</time_frame>
    <description>To determine whether adjunctive sertraline will lead to a faster rate of fungal clearance from cerebrospinal fluid (CSF), as measured by early fungicidal activity (EFA) of clearance of the Cryptococcus colony forming units (cfu) per mL of CSF per day, compared to standard therapy alone.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IRIS and Relapse Incidence</measure>
    <time_frame>18 weeks</time_frame>
    <description>Cumulative incidence of central nervous system (CNS) cryptococcal-related paradoxical immune reconstitution inflammatory syndrome (IRIS) or culture-positive relapse</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event free survival</measure>
    <time_frame>18 weeks</time_frame>
    <description>Event free survival of composite events of: death,central nervous system (CNS) cryptococcal-related paradoxical immune reconstitution inflammatory syndrome (IRIS) or culture-positive relapse.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Cost analysis</measure>
    <time_frame>18 weeks</time_frame>
    <description>Cost-benefit of adjunctive sertraline therapy</description>
  </other_outcome>
  <other_outcome>
    <measure>Switching to Open Label Sertraline</measure>
    <time_frame>14 weeks</time_frame>
    <description>Incidence of switching from blinded to open-labeled study drug due to severe depression occurring between 4 to 14 weeks.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">550</enrollment>
  <condition>Cryptococcal Meningitis</condition>
  <condition>Fungal Meningitis</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Standard cryptococcal meningitis therapy with amphotericin (0.7-1.0 mg/kg/day) + fluconazole (800-1200mg/day).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sertraline 400mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Standard cryptococcal meningitis therapy with amphotericin (0.7-1.0 mg/kg/day) + fluconazole (800-1200mg/day plus adjunctive sertraline therapy at 400mg/day for 2 weeks, then 200mg for 12 weeks, and then tapered over 3 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sertraline</intervention_name>
    <description>Sertraline 400mg/day for 2 weeks, then 200mg/day for 12 weeks, then tapered over 3 weeks.</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Sertraline 400mg</arm_group_label>
    <other_name>Zoloft</other_name>
    <other_name>Lustral</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Cryptococcal meningitis diagnosed by CSF cryptococcal antigen (CRAG)

          -  HIV-1 infection

          -  Ability and willingness of the participant or legal guardian/representative to
             provide informed consent

          -  Willing to receive protocol-specified lumbar punctures

        Exclusion Criteria:

          -  Age &lt; 18 years

          -  Receipt of &gt;=3 doses of amphotericin therapy

          -  Cannot or unlikely to attend regular clinic visits

          -  History of known liver cirrhosis

          -  Presence of jaundice

          -  Pregnancy

          -  Current breastfeeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David B Meya, MBCHB MMed</last_name>
    <role>Principal Investigator</role>
    <affiliation>Infectious Disease Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Joshua Rhein, MD</last_name>
    <role>Study Director</role>
    <affiliation>University of Minnesota - Clinical and Translational Science Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David R Boulware, MD MPH</last_name>
    <role>Study Chair</role>
    <affiliation>University of Minnesota - Clinical and Translational Science Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>David B Meya, MBChB MMed</last_name>
    <email>david.meya@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>David R Boulware, MD MPH</last_name>
    <email>boulw001@umn.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ifakara Health Institute</name>
      <address>
        <city>Ifakara</city>
        <country>Tanzania</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Emili Letang, MD, MSc, PhD</last_name>
      <phone>+255 787 736 169</phone>
      <email>emili.letang@unibas.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Infectious Disease Institute</name>
      <address>
        <city>Kampala</city>
        <country>Uganda</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Darlisha Williams, MPH</last_name>
      <email>coat.trial@gmail.com</email>
    </contact>
    <investigator>
      <last_name>David B Meya, MBChB MMed</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mbarara University of Science and Technology</name>
      <address>
        <city>Mbarara</city>
        <country>Uganda</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Conrad Muzoora, MMed</last_name>
      <email>conradmuzoora@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Kabanda Taseera, MMed MSc</last_name>
      <email>kabtash@yahoo.com</email>
    </contact_backup>
    <investigator>
      <last_name>Conrad Muzoora, MMed</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kabanda Taseera, MMed MSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Tanzania</country>
    <country>Uganda</country>
  </location_countries>
  <link>
    <url>http://www.idi-makerere.com/</url>
    <description>Infectious Disease Institute</description>
  </link>
  <link>
    <url>http://www.accordiafoundation.org</url>
    <description>Accordia Global Health Foundation</description>
  </link>
  <reference>
    <citation>Rhein J, Morawski BM, Hullsiek KH, Nabeta HW, Kiggundu R, Tugume L, Musubire A, Akampurira A, Smith KD, Alhadab A, Williams DA, Abassi M, Bahr NC, Velamakanni SS, Fisher J, Nielsen K, Meya DB, Boulware DR; ASTRO-CM Study Team.. Efficacy of adjunctive sertraline for the treatment of HIV-associated cryptococcal meningitis: an open-label dose-ranging study. Lancet Infect Dis. 2016 Jul;16(7):809-18. doi: 10.1016/S1473-3099(16)00074-8. Epub 2016 Mar 10.</citation>
    <PMID>26971081</PMID>
  </reference>
  <reference>
    <citation>Zhai B, Wu C, Wang L, Sachs MS, Lin X. The antidepressant sertraline provides a promising therapeutic option for neurotropic cryptococcal infections. Antimicrob Agents Chemother. 2012 Jul;56(7):3758-66. doi: 10.1128/AAC.00212-12. Epub 2012 Apr 16.</citation>
    <PMID>22508310</PMID>
  </reference>
  <reference>
    <citation>Smith KD, Achan B, Hullsiek KH, McDonald TR, Okagaki LH, Alhadab AA, Akampurira A, Rhein JR, Meya DB, Boulware DR, Nielsen K; ASTRO-CM/COAT Team.. Increased Antifungal Drug Resistance in Clinical Isolates of Cryptococcus neoformans in Uganda. Antimicrob Agents Chemother. 2015 Dec;59(12):7197-204. doi: 10.1128/AAC.01299-15. Epub 2015 Aug 31.</citation>
    <PMID>26324276</PMID>
  </reference>
  <verification_date>December 2016</verification_date>
  <lastchanged_date>December 6, 2016</lastchanged_date>
  <firstreceived_date>February 27, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cryptococcal meningitis</keyword>
  <keyword>cryptococcus</keyword>
  <keyword>meningitis</keyword>
  <keyword>yeast</keyword>
  <keyword>fungus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Meningitis</mesh_term>
    <mesh_term>Meningitis, Cryptococcal</mesh_term>
    <mesh_term>Meningitis, Fungal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Sertraline</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
